We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

1.
Figure 3

Figure 3. Cost-effectiveness acceptance curves (CEAC). From: COST EFFECTIVENESS OF CARDIAC RESYNCHRONIZATION FOR THE PREVENTION OF HEART FAILURE.

Cost-effectiveness acceptance curves (CEAC) represent the probability that the CRT-ICD is cost-effective compared to ICD only, for different willingness to pay (WTP) values. Here we present CEACs for all patients, unrestricted by heart failure events, using either life years (LY) or quality-adjusted life years (QALY) as effectiveness measures.

Katia Noyes, et al. J Cardiovasc Electrophysiol. ;24(1):66-74.
2.
Figure 2

Figure 2. Accumulated costs, lifetimes, quality-adjusted life years (QALY) and resulting incremental cost-effectiveness ratios (iCERs), limited to heart failure-free years, for left bundle branch block (LBBB) patients, by active device and by years. From: COST EFFECTIVENESS OF CARDIAC RESYNCHRONIZATION FOR THE PREVENTION OF HEART FAILURE.

All costs and (quality-adjusted) lifetimes are discounted at 3% per annum and are estimated out to a limited time horizon, in years; here, lifetimes (but not costs) are restricted by occurrence of heart failure events, that is, heart failure-free years. Extrapolation beyond 4 years would require many additional assumptions and is not attempted. The bars indicate 95% confidence limits for the estimates. Due to no significantly higher costs in the CRT-ICD group at years 3 and 4, the lower confidence limits of iCER are negative (and not displayed). Numerical values for year 4 appear in Table 3.

Katia Noyes, et al. J Cardiovasc Electrophysiol. ;24(1):66-74.
3.
Figure 1

Figure 1. Accumulated costs, lifetimes, quality-adjusted life years (QALY) and resulting incremental cost-effectiveness ratios (iCERs), unrestricted by heart failure events, for left bundle branch block (LBBB) patients, by active device and by years. From: COST EFFECTIVENESS OF CARDIAC RESYNCHRONIZATION FOR THE PREVENTION OF HEART FAILURE.

All costs and (quality-adjusted) lifetimes are discounted at 3% per annum and are estimated out to a limited time horizon, in years; here, they are unrestricted by occurrence of heart failure events. Extrapolation beyond 4 years would require many additional assumptions and is not attempted. The bars indicate 95% confidence limits for the estimates. Since there is no significant gain in years of life at year 1, the upper limit for year-based iCER goes to infinity; the upper limit for QALY-based iCER at year 1 is 4626. Due to no significantly higher costs in the CRT-ICD group at years 3 and 4, the lower confidence limits of iCER are negative (and not displayed). Numerical values for year 4 appear in Table 3.

Katia Noyes, et al. J Cardiovasc Electrophysiol. ;24(1):66-74.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk